CN116323632B - 两性霉素b的杂交酰胺衍生物 - Google Patents

两性霉素b的杂交酰胺衍生物 Download PDF

Info

Publication number
CN116323632B
CN116323632B CN202180066848.2A CN202180066848A CN116323632B CN 116323632 B CN116323632 B CN 116323632B CN 202180066848 A CN202180066848 A CN 202180066848A CN 116323632 B CN116323632 B CN 116323632B
Authority
CN
China
Prior art keywords
compound
compounds
amb
acid
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180066848.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN116323632A (zh
Inventor
M·D·伯克
A·马吉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois System filed Critical University of Illinois System
Publication of CN116323632A publication Critical patent/CN116323632A/zh
Application granted granted Critical
Publication of CN116323632B publication Critical patent/CN116323632B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08Hetero rings containing eight or more ring members, e.g. erythromycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CN202180066848.2A 2020-08-10 2021-08-09 两性霉素b的杂交酰胺衍生物 Active CN116323632B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063063655P 2020-08-10 2020-08-10
US63/063655 2020-08-10
US202163175771P 2021-04-16 2021-04-16
US63/175771 2021-04-16
PCT/US2021/045205 WO2022035752A1 (en) 2020-08-10 2021-08-09 Hybrid amide derivatives of amphotericin b

Publications (2)

Publication Number Publication Date
CN116323632A CN116323632A (zh) 2023-06-23
CN116323632B true CN116323632B (zh) 2024-12-31

Family

ID=80247344

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180066848.2A Active CN116323632B (zh) 2020-08-10 2021-08-09 两性霉素b的杂交酰胺衍生物

Country Status (12)

Country Link
US (1) US20230357303A1 (https=)
EP (2) EP4696379A3 (https=)
JP (1) JP7656359B2 (https=)
KR (1) KR20230061405A (https=)
CN (1) CN116323632B (https=)
AU (1) AU2021325676A1 (https=)
CA (1) CA3190997A1 (https=)
ES (1) ES3061451T3 (https=)
IL (1) IL300441A (https=)
MX (1) MX2023001649A (https=)
PT (1) PT4192248T (https=)
WO (1) WO2022035752A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL122086B1 (en) * 1979-04-09 1982-06-30 Politechnika Gdanska Process for preparing amides of antibiotics from the group of polyene macrolides and their derivativesvykh makrolidov i ikh proizvodnykh
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US6664241B2 (en) * 2000-05-31 2003-12-16 Micrologix Biotech Inc. Water-soluble amide derivatives of polyene macrolides and preparation and uses thereof
JP6543272B2 (ja) * 2014-05-16 2019-07-10 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイThe Board Of Trustees Of The University Of Illinois 低減された毒性を有するアンホテリシンb誘導体
TWI702223B (zh) * 2014-06-12 2020-08-21 日商塩野義製藥股份有限公司 多烯巨環內酯衍生物
CA3021061C (en) * 2015-04-15 2023-10-24 Martin D. Burke Derivatives of amphotericin b
JP7477177B2 (ja) * 2018-09-07 2024-05-01 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ 毒性が低減されたハイブリッドアムホテリシンb誘導体
EP4009985A4 (en) * 2019-08-08 2023-09-06 The Board Of Trustees Of The University Of Illinois HYBRID AMIDE DERIVATIVES OF AMPHOTERICIN B

Also Published As

Publication number Publication date
ES3061451T3 (en) 2026-04-01
JP2023537921A (ja) 2023-09-06
EP4192248B1 (en) 2025-12-03
JP7656359B2 (ja) 2025-04-03
IL300441A (en) 2023-04-01
WO2022035752A1 (en) 2022-02-17
EP4696379A3 (en) 2026-02-25
EP4192248A1 (en) 2023-06-14
CA3190997A1 (en) 2022-02-17
EP4192248A4 (en) 2024-12-04
AU2021325676A1 (en) 2023-03-30
MX2023001649A (es) 2023-04-24
US20230357303A1 (en) 2023-11-09
KR20230061405A (ko) 2023-05-08
CN116323632A (zh) 2023-06-23
EP4696379A2 (en) 2026-02-18
PT4192248T (pt) 2026-02-11

Similar Documents

Publication Publication Date Title
US11970512B2 (en) Amphotericin B derivatives with improved therapeutic index
KR20220071185A (ko) 암포테리신 b의 하이브리드 아미드 유도체
WO2014165676A1 (en) Amphotericin b derivative with reduced toxicity
US11198705B2 (en) Hybrid Amphotericin B derivatives with reduced toxicity
CN116323632B (zh) 两性霉素b的杂交酰胺衍生物
CN115515599A (zh) 化合物在真菌感染的治疗中的用途
AU2020329149A1 (en) Combination treatment of systemic fungal infections
JP2024519342A (ja) 自己免疫性、同種免疫性、炎症性、及びミトコンドリア性の状態を治療するための組成物、ならびにその使用
KR20220058547A (ko) 감소된 독성을 갖는 하이브리드 암포테리신 b 유도체
JP2025521628A (ja) カルシニューリン阻害剤の間欠的投与のための組成物
HK40086224A (zh) 化合物在真菌感染的治疗中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant